Roche's Vabysmo shows potential to treat eye disorder common in Asia

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. In its first full year on the market, the age-related macular degeneration (AMD) treatment racked up sales of 2.4 billion Swiss francs ($2.8 billion). This year through nine months, the bispecific antibody has already topped that figure, even though its momentum has slowed.